In the high-stakes world of biotech, a $656M funding round usually comes with a splashy website, aggressive SEO, and digital buzz. Relypsa has neither. The company's digital footprint is virtually zero, making it one of the most fascinating anomalies in the science and education sector.

"A biotech unicorn with no digital shadow—Relypsa proves that in science, the product is the proof, not the page views."

The team structure reveals their priorities: a Medical Science Director, multiple Territory Managers, and Territory Account Managers suggest they're in late-stage commercialization. They're not building brand awareness—they're preparing for launch. The zero traffic isn't a failure; it's a firewall.

• Zero web presence = zero distraction from core science
• Territory Managers indicate imminent commercial launch
• 110-person team optimized for clinical, not marketing, execution
• $656M funding suggests massive potential market (likely cardiology or nephrology)